All In Biotech

Drug Trial Radar · NCT05230537

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Feb 17, 2022

Primary completion

Aug 19, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

  • Iptacopan (LNP023)Drug

    oral capsules

  • PlaceboDrug

    oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degeneration (AMD) in the early/intermediate AMD eye as determined by optical coherence tomography (OCT) & supported by multimodal imagingTime frame: Baseline/Day 1 through Month 24

Locations

28 sites in 4 countries. Site status is shown where the registry gives one.

  • Retina Consultants of Orange County

    Fullerton, California

  • Salehi Retina Institute

    Huntington Beach, California

  • Martel Eye Medical Group

    Rancho Cordova, California

  • Retinal Consultants Medical Group Inc

    Sacramento, California

  • California Retina Consultants

    Santa Barbara, California

  • Southwest Retina Research Center

    Durango, Colorado

  • Advanced Research LLC

    Deerfield Beach, Florida

  • Retina Center Of South Florida

    Delray Beach, Florida

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida

  • Midwest Eye Institute

    Carmel, Indiana

  • Retina Associates New Orleans

    Metairie, Louisiana

  • Retina Care Center

    Baltimore, Maryland

  • Opthamalic Consultants of Boston

    Boston, Massachusetts

  • Envision Ocular LLC

    Bloomfield, New Jersey

  • Duke Eye Center

    Durham, North Carolina

  • Retina Northwest PC

    Portland, Oregon

  • Charles Retina Institute

    Germantown, Tennessee

  • Austin Research Center for Retina

    Austin, Texas

  • Retina Consultants TX Rsrch Ctr

    Bellaire, Texas

  • Retina Foundation

    Dallas, Texas

  • Texas Retina Associates

    Fort Worth, Texas

  • Retina Consultants of Houston PA

    Houston, Texas

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Harbin, Heilongjiang, China

  • Novartis Investigative Site

    Tianjin, Tianjin Municipality, China

  • Emanuelli Research and Development Center LLC

    Arecibo, Puerto Rico

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.